Ovid Therapeutics CEO and leadership

Jeremy Levin (born 1954) is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry.

Matthew During, M.D., D.Sc., is our founder and served as our chief scientific officer from March 2015 to May 2019 and has been a member of our board of directors from April 2014 to May 2019. He served as our chief executive officer from April 2014 to March 2015. Prior to founding our company, Dr. During founded Nightstar Therapeutics, a gene therapy company, in October 2013 and served as a consultant until November 2015. He co-founded Vector Neurosciences, another gene therapy company in January 2014, serving as CEO, subsequently sold in October 2018 to MeiraGTX. Most recently, he founded Emrys Bio where he serves as President. From February 2014 to December 2014, Dr. During served as a senior manager at Bridgewater Associates. Prior to that, he founded Neurologix Inc., a pharmaceutical company, in October 1999 and served as a member of its scientific advisory board until March 2012. Dr. During also co-founded Merlin Pharmaceuticals Limited, a pharmaceutical company, in February 1993 and served as a member of its scientific advisory board until December 1994. Dr. During previously served on the faculty of Yale University as a professor of neurosurgery from 1989 to 2000, as a professor at Cornell University until 2006 and Ohio State University from 2006 to December 2014, where he currently serves as an adjunct professor. Since 2011, he has also served as a visiting professor of translational neuroscience at the University of Oxford. Dr. During earned his B.S., M.D. and D.Sc. from the University of Auckland. He also completed fellowships at Massachusetts Institute of Technology, Harvard Medical School, Massachusetts General Hospital and Yale University.

Jeffrey Rona is the Chief Business Officer at Ovid. He is responsible for leading Ovid’s capital formation with investor groups and strategic corporate partnerships. Mr. Rona joined Ovid as consulting chief financial officer in 2019 to assist the company with strategic financings, including Ovid’s partnership with Angelini. He brings more than 25 years of experience to the role, both as a former investment banker and a strategic financial executive with expertise in financial operations, investor relations and raising capital for public and private companies. He previously held senior leadership positions for GlobeImmune, AlgoRx Pharmaceuticals and Antigenics, and later formed a successful life sciences financial advisory practice. Mr. Rona began his career at Coopers & Lybrand and UBS Investment Bank, and holds a B.S. in accounting from Case Western Reserve University.

Jason Tardio is a CCO at Ovid Therapeutics.

Thomas 'Tom' Perone is a Chief Compliance Ofcr/Secy/Gen Counsel at Ovid Therapeutics and is based in Greater New York City Area. He has worked as Senior Corporate Counsel at CELGENE CORP, Senior Dir:Legal at Imclone Systems, and Associate at Proskauer Rose LLP. Thomas attended Seton Hall University School of Law between 1993 and 1997, Rutgers University between 1982 and 1986, and Fairleigh Dickinson University between 1991 and 1993.

Matthew During, M.D., D.Sc., is our founder and served as our chief scientific officer from March 2015 to May 2019 and has been a member of our board of directors from April 2014 to May 2019. He served as our chief executive officer from April 2014 to March 2015. Prior to founding our company, Dr. During founded Nightstar Therapeutics, a gene therapy company, in October 2013 and served as a consultant until November 2015. He co-founded Vector Neurosciences, another gene therapy company in January 2014, serving as CEO, subsequently sold in October 2018 to MeiraGTX. Most recently, he founded Emrys Bio where he serves as President. From February 2014 to December 2014, Dr. During served as a senior manager at Bridgewater Associates. Prior to that, he founded Neurologix Inc., a pharmaceutical company, in October 1999 and served as a member of its scientific advisory board until March 2012. Dr. During also co-founded Merlin Pharmaceuticals Limited, a pharmaceutical company, in February 1993 and served as a member of its scientific advisory board until December 1994. Dr. During previously served on the faculty of Yale University as a professor of neurosurgery from 1989 to 2000, as a professor at Cornell University until 2006 and Ohio State University from 2006 to December 2014, where he currently serves as an adjunct professor. Since 2011, he has also served as a visiting professor of translational neuroscience at the University of Oxford. Dr. During earned his B.S., M.D. and D.Sc. from the University of Auckland. He also completed fellowships at Massachusetts Institute of Technology, Harvard Medical School, Massachusetts General Hospital and Yale University.

Jeremy Levin (born 1954) is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry.